cervical cancer detection News
-
Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution
Guided Therapeutics, Inc. or the “Company” (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has raised an additional US $1.13 million under the terms of a 3-year convertible debenture. The proceeds are intended to pay off an existing convertible note that matures at the end of 2021. The convertible ...
-
Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that testing of 150 patients has been completed in the ongoing clinical trial for Chinese National Medical Products Administration (NMPA) approval. The trial is underway at four sites in China. The trial is expected to be completed in the second quarter of this year and submitted for approval ...
-
Guided Therapeutics Closes $2.114 Million Series F Preferred Stock Financing
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had closed its Series F Preferred Stock Financing on March 26, 2021. This oversubscribed sale of 2,114 Series F Preferred Shares resulted in gross proceeds to the Company of $2,114,000, netting approximately $1,980,000 after legal costs, ...
-
New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that an independent study of 166 women in Hungary showed that LuViva detected 20% more cervical precancer and cancer than the HPV test. Specifically, LuViva had a very high sensitivity of 94%, detecting disease in 48 of 51 women with biopsy results ...
-
Guided Therapeutics Raises US $1.1 Million in New Preferred Stock Offering
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has thus far raised a total of US $1.1 million under the terms of a Series F Preferred Stock Offering. The private placement offering targeted at least U.S. $1 million and the financing can continue to raise additional funds until ...
-
The Netherlands started QIAsure Methylation Test implementation trial for triage of HPV positively screened women
With the introduction of HPV based screening in 2017 the Dutch cervical cancer screening program underwent an important improvement. More women at risk are being discovered due to the higher sensitivity of HPV assays compared to the old cytology based test program, but as a consequence the number of referrals after cytology based triage of HPV positive women has increased 3 times. The ...
-
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva™ Advanced Cervical Scan, based on its patented biophotonic technology, announced today its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI), has received notice from the Jinan Medical Device Quality Supervision and Testing Center of the State Food and Drug ...
-
Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that enrollment and testing of patients has begun at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai. The data will be submitted to the Chinese National Medical Products Administration (NMPA; formerly ...
-
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai. Clinical trials there and at three other centers are expected to begin this quarter. GTHP also ...
-
Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that its Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI), had received ethics board approval and placed LuViva devices at two of the three participating hospitals for clinical trials aimed at achieving Chinese FDA approval. ...
-
Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva Advanced Cervical Scan Premarket Approval Application
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company’s plan to submit an approvable application for the LuViva® Advanced Cervical Scan. The LuViva is designed to detect cervical ...
-
Guided Therapeutics Ships First Four LuViva Advanced Cervical Scans for $14 million Turkish Ministry of Health Order
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has shipped the first four LuViva® Advance Cervical Scan units to its Turkish distributor for its order with the Turkish Ministry of Health (MOH). In total, the company plans to ship 25 LuViva units and 40,000 disposable Cervical ...
-
Guided Therapeutics Turkish Distributor Doubles Order for LuViva Advanced Cervical Scan Single-Use Disposables for Turkish Ministry of Health
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has received an increased order for disposable Cervical Guides from the Turkish Ministry of Health (MOH). The order has more than doubled to 1.1 million disposable Cervical Guides from a ...
-
VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018
VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging research findings will be presented at the upcoming 2018 American Association of Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018. The abstract presentation includes a breakthrough research study using the ...
-
Novosanis research grant
Research grant of (up to) € 25 000 in support of the most impactful proposal and (up to) 200 Colli-Pee urine collection devices for use with the project. Novosanis is offering a research grant exclusive to EACR members to stimulate innovative research in cancer biomarker detection using urine as a sample type. As urine sampling is easy, quick and non-invasive it has the potential to change ...
By Novosanis NV
-
VisionGate is Leveraging the Cell-CT Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
VisionGate, a clinical stage oncology pharmaceutical and diagnosticscompany, is pleased to announce today the advancement of its breakthrough technology Cell-CT platform. The first shipment of commercial-capable Cell-CT systems were delivered to VisionGate’s clinical laboratory in Phoenix, Arizona earlier this year, setting the stage for the company’s advancement. “I am pleased ...
-
Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells that have undergone Malignancy Associated Change
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its CellCT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. These non-cancerous cells have been affected by the presence of the cancer cells and have undergone ...
-
Results and Presentation of Important New Research at the 2018 IASLC World Conference on Lung Cancer
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada. These studies demonstrate important new morphometric detection findings of the Cell-CT™ platform and the LuCED® ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you